State-of-the-art pharmacotherapy for diabetic neuropathy

References

• IDF. IDF Diabetes Atlas. 8th Edition ed. Web; 2017 [cited 2020 Jun 1]. Available from: https://www.idf.org/e-library/welcome.html
   Google Scholar
• Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41. DOI:https://doi.org/10.1038/s41572-019-0092-1.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Nevoret ML, Casellini C, et al. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42(4):747–787.
   PubMed Web of Science ®Google Scholar
• Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author’s transl)]. Diabetes Metab. 1977;3(4):245–256.
   Google Scholar
• Rf Br H, Dabelea D, D’Agostino RB Jr, et al. The SEARCH for Diabetes in Youth Study: Rationale, Findings, and Future Directions. Diabetes Care. 2014;37(12):3336–3344.
   PubMed Web of Science ®Google Scholar
• Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with Type 1 and Type 2 diabetes: search for diabetes in youth study. Diabetes care. 2017;40(9):1226–1232. DOI:https://doi.org/10.2337/dc17-0179.
   PubMed Web of Science ®Google Scholar
• Abbott CA, Malik RA, van Ross ER, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the. UK Diabetes Care. 2011;34(10):2220–2224. DOI:https://doi.org/10.2337/dc11-1108.
   PubMed Web of Science ®Google Scholar
• Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21(9):976–982.
   PubMed Web of Science ®Google Scholar
• Sadosky A, Hopper J, Parsons B. Painful diabetic peripheral neuropathy: results of a survey characterizing the perspectives and misperceptions of patients and healthcare practitioners. Patient. 2014;7(1):107–114.
   PubMedGoogle Scholar
• Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain. 2006;22(8):681–685.
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30(4):374–385.
   PubMed Web of Science ®Google Scholar
• Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006;20(1):26–33.
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. j pain. 2006;7(12):892–900.
   PubMed Web of Science ®Google Scholar
• Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5(1):17–39.
   PubMedGoogle Scholar
• Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4(1):4–18.
   PubMed Web of Science ®Google Scholar
• Arif ZA, Shaikh IA, Masood N. Cardiovascular autonomic neuropathy (CAN) in patients of type 2 diabetes mellitus: a tertiary care hospital based study. Indian Heart J. 2014;66(6):751–754.
   PubMedGoogle Scholar
• Williams SM, Eleftheriadou A, Alam U, et al. Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. Diabetes Ther. 2019;10(6):1995–2021.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia. 1998;41(4):416–423. DOI:https://doi.org/10.1007/s001250050924
   PubMed Web of Science ®Google Scholar
• Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: Where are we now and where to go?. J Diabetes Investig. 2011;2(1):18–32.
   PubMed Web of Science ®Google Scholar
• Thrainsdottir S, Malik RA, Dahlin LB, et al. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. Diabetes. 2003;52(10):2615–2622. DOI:https://doi.org/10.2337/diabetes.52.10.2615.
   PubMed Web of Science ®Google Scholar
• Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia. 2005;48(3):578–585. DOI:https://doi.org/10.1007/s00125-004-1663-5.
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes care. 2010;33(7):1578–1584. DOI:https://doi.org/10.2337/dc10-0125.
   PubMed Web of Science ®Google Scholar
• Malik RA. Why are there no good treatments for diabetic neuropathy?. Lancet Diabetes Endocrinol. 2014;2(8):607–609.
   PubMed Web of Science ®Google Scholar
• Javed S, Alam U, Malik RA. Treating diabetic neuropathy: present strategies and emerging solutions. The review of diabetic studies: RDS. 2015;12(1–2):63–83.
   PubMedGoogle Scholar
• Malik RA. Wherefore Art Thou, O Treatment for Diabetic Neuropathy?. Int Rev Neurobiol. 2016;127:287–317.
   PubMed Web of Science ®Google Scholar
• Bitirgen G, Ozkagnici A, Malik RA, et al. Corneal nerve fibre damage precedes diabetic retinopathy in patients with type 2 diabetes mellitus. Diabet Med. 2014;31(4):431–438.
   PubMed Web of Science ®Google Scholar
• Malik RA. Which test for diagnosing early human diabetic neuropathy?. Diabetes. 2014;63(7):2206–2208.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes. 2014;63(7):2454–2463. DOI:https://doi.org/10.2337/db13-1819.
   PubMed Web of Science ®Google Scholar
• Alam U, Jeziorska M, Petropoulos IN, et al. Diagnostic utility of corneal confocal microscopy and intra-epidermal nerve fibre density in diabetic neuropathy. PLoS One. 2017;12(7):e0180175. DOI:https://doi.org/10.1371/journal.pone.0180175.
   PubMed Web of Science ®Google Scholar
• Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294–1299. DOI:https://doi.org/10.2337/dc06-0224.
   PubMed Web of Science ®Google Scholar
• Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007;56(8):2148–2154. DOI:https://doi.org/10.2337/db07-0285.
   PubMed Web of Science ®Google Scholar
• Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care. 2007;30(10):2608–2612. DOI:https://doi.org/10.2337/dc07-0870.
   PubMed Web of Science ®Google Scholar
• Ang L, Jaiswal M, Martin C, et al. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528.
   PubMed Web of Science ®Google Scholar
• Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6(6):CD007543–CD.
   Google Scholar
• Pop-Busui R, Herman WH, Feldman EL, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010;10(4):276–282. DOI:https://doi.org/10.1007/s11892-010-0120-8.
   PubMed Web of Science ®Google Scholar
• Testa R, Bonfigli AR, Prattichizzo F, et al. “Metabolic memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications. Nutrients. 2017;9:5.
   Web of Science ®Google Scholar
• Azmi S, Jeziorska M, Ferdousi M, et al. Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. Diabetologia. 2019;62(8):1478–1487. DOI:https://doi.org/10.1007/s00125-019-4897-y.
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117. DOI:https://doi.org/10.1016/0168-8227(95)01064-K.
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. DOI:https://doi.org/10.1016/S0140-6736(10)60576-4.
   PubMed Web of Science ®Google Scholar
• Calles-Escandon J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes care. 2010;33(4):721–727. DOI:https://doi.org/10.2337/dc09-1471.
   PubMed Web of Science ®Google Scholar
• Knabl J, Witschi R, Hosl K, et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature. 2008;451(7176):330–334. DOI:https://doi.org/10.1038/nature06493.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–350. DOI:https://doi.org/10.1056/NEJMoa032782.
   PubMed Web of Science ®Google Scholar
• Wiggin TD, Sullivan KA, Pop-Busui R, et al. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58(7):1634–1640.
   PubMed Web of Science ®Google Scholar
• Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complications study. Diabetes. 1989;38(11):1456–1461. DOI:https://doi.org/10.2337/diab.38.11.1456.
   PubMed Web of Science ®Google Scholar
• Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh epidemiology of diabetes complications study experience. Diabetes. 2006;55(5):1463–1469.
   PubMed Web of Science ®Google Scholar
• Davis TM, Yeap BB, Davis WA, et al. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle diabetes study. Diabetologia. 2008;51(4):562–566.
   PubMed Web of Science ®Google Scholar
• Villegas-Rivera G, Roman-Pintos LM, Cardona-Munoz EG, et al. Effects of ezetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: a randomized, double-blind, placebo-controlled clinical trial. Oxid Med Cell Longev. 2015;2015:756294.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV, Magnusson P, LeQuang JA, et al. Statins and neuropathic pain: a narrative review. Pain Ther. 2020;9(1):97–111.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III study group. Alpha-Lipoic acid in diabetic neuropathy. Diabetes care. 1999;22(8):1296–1301. DOI:https://doi.org/10.2337/diacare.22.8.1296.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997;20(3):369–373.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–2370. DOI:https://doi.org/10.2337/dc06-1216.
   PubMed Web of Science ®Google Scholar
• Reja A, Tesfaye S, Harris ND, et al. Is ACE inhibition with Lisinopril helpful in diabetic neuropathy?. Diabetic Med. 1995;12(4):307–309.
   PubMed Web of Science ®Google Scholar
• Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet. 1998;352(9145):1978–1981. DOI:https://doi.org/10.1016/S0140-6736(98)02478-7.
   PubMed Web of Science ®Google Scholar
• Kontopoulos AG, Athyros VG, Didangelos TP, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care. 1997;20(3):355–361. DOI:https://doi.org/10.2337/diacare.20.3.355.
   PubMed Web of Science ®Google Scholar
• Didangelos T, Tziomalos K, Margaritidis C, et al. Efficacy of Administration of an Angiotensin converting enzyme inhibitor for two years on autonomic and peripheral neuropathy in patients with diabetes mellitus. J Diabetes Res. 2017;2017:6719239.
   PubMed Web of Science ®Google Scholar
• Gæde P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med. 2003;348(5):383–393.
   Google Scholar
• Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298–2307. DOI:https://doi.org/10.1007/s00125-016-4065-6.
   PubMed Web of Science ®Google Scholar
• Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–551. DOI:https://doi.org/10.1016/S0140-6736(17)33102-1.
   PubMed Web of Science ®Google Scholar
• Sheng B, Truong K, Spitler H, et al. Effects of Bariatric surgery on Type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes Surg. 2017;27(10):2724–2732.
   PubMed Web of Science ®Google Scholar
• Siahmansur TJ, Liu Y, Azmi S, et al. Improvement in small fibre neuropathy and inflammatory biomarkers after bariatric surgery. Atherosclerosis. 2016;255:8–9.
   Web of Science ®Google Scholar
• Muller-Stich BP, Fischer L, Kenngott HG, et al. Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization–results of a prospective cohort study (DiaSurg 1 study). Ann Surg. 2013;258(5):760–765. discussion 5-6. doi:https://doi.org/10.1097/SLA.0b013e3182a618b2.
   PubMed Web of Science ®Google Scholar
• Aghili R, Malek M, Tanha K, et al. The effect of Bariatric surgery on peripheral polyneuropathy: a systematic review and meta-analysis. Obes Surg. 2019;29(9):3010–3020.
   PubMed Web of Science ®Google Scholar
• Cohen R, Pechy F, Petry T, et al. Bariatric and metabolic surgery and microvascular complications of type 2 diabetes mellitus. Jornal brasileiro de nefrologia: ‘orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. Braz J Nephrol. 2015;37(3):399–409. DOI:https://doi.org/10.5935/0101-2800.20150061
   PubMedGoogle Scholar
• Hamel J, Logigian EL. Acute nutritional axonal neuropathy. Muscle Nerve. 2018;57(1):33–39.
   PubMed Web of Science ®Google Scholar
• Javed S, Petropoulos IN, Alam U, et al. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6(1):15–28.
   PubMed Web of Science ®Google Scholar
• Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019;20(Suppl 1):S2–S12. DOI:https://doi.org/10.1093/pm/pnz075.
   PubMed Web of Science ®Google Scholar
• Vollert J, Maier C, Attal N, et al. Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. Pain. 2017;158(8):1446–1455. DOI:https://doi.org/10.1097/j.pain.0000000000000935.
   PubMed Web of Science ®Google Scholar
• Holbech JV, Bach FW, Finnerup NB, et al. Pain phenotype as a predictor for drug response in painful polyneuropathy-a retrospective analysis of data from controlled clinical trials. Pain. 2016;157(6):1305–1313.
   PubMed Web of Science ®Google Scholar
• Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014;155(11):2263–2273. DOI:https://doi.org/10.1016/j.pain.2014.08.014.
   PubMed Web of Science ®Google Scholar
• Demant DT, Lund K, Finnerup NB, et al. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study. Pain. 2015;156(11):2234–2244. DOI:https://doi.org/10.1097/j.pain.0000000000000266.
   PubMed Web of Science ®Google Scholar
• Lee-Kubli C, Marshall AG, Malik RA, et al. The H-reflex as a biomarker for spinal disinhibition in painful diabetic neuropathy. Curr Diab Rep. 2018;18(1):1.
   PubMed Web of Science ®Google Scholar
• Marshall AG, Lee-Kubli C, Azmi S, et al. Spinal disinhibition in experimental and clinical painful diabetic neuropathy. Diabetes. 2017;66(5):1380–1390. DOI:https://doi.org/10.2337/db16-1181.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616–2625.
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Wilhelm S, Schacht A, et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study. PAIN®. 2014;155(10):2171–2179. DOI:https://doi.org/10.1016/j.pain.2014.08.020.
   PubMed Web of Science ®Google Scholar
• Botney M, Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol. 1983;13(2):160–164.
   PubMed Web of Science ®Google Scholar
• Benbouzid M, Gaveriaux-Ruff C, Yalcin I, et al. Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol Psychiatry. 2008;63(6):633–636. DOI:https://doi.org/10.1016/j.biopsych.2007.06.016.
   PubMed Web of Science ®Google Scholar
• de Gandarias JM, Echevarria E, Acebes I, et al. Effects of imipramine administration on mu-opioid receptor immunostaining in the rat forebrain. Arzneimittelforschung. 1998;48(7):717–719.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–251. DOI:https://doi.org/10.1016/j.pain.2007.08.033.
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care. 2017;40(1):136–154. DOI:https://doi.org/10.2337/dc16-2042.
   PubMed Web of Science ®Google Scholar
• Bril V, Franklin EJ, Backonja GM, et al. Treatment of painful diabetic neuropathy. Neurology. 2011;77(6):603.
   Google Scholar
• Kvinesdal B, Molin J, Frøland A, et al. Imipramine treatment of painful diabetic neuropathy. JAMA. 1984;251(13):1727–1730.
   PubMed Web of Science ®Google Scholar
• Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007(4):CD005454. Published 2007 Oct 17. DOI:https://doi.org/10.1002/14651858.CD005454.pub2.
   Google Scholar
• Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014(1):CD007115.
   Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1–2):109–118.
   PubMed Web of Science ®Google Scholar
• Wasan AD, Ossanna MJ, Raskin J, et al. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Curr Drug Saf. 2009;4(1):22–29. DOI:https://doi.org/10.2174/157488609787354404.
   PubMedGoogle Scholar
• Trouvin AP, Perrot S, Lloret-Linares C. Efficacy of Venlafaxine in neuropathic pain: a narrative review of optimized treatment. Clin Ther. 2017;39(6):1104–1122.
   PubMed Web of Science ®Google Scholar
• Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161(9):639–649.
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697–706.
   PubMed Web of Science ®Google Scholar
• Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res. 2014;7:339–351.
   PubMed Web of Science ®Google Scholar
• Backonja MM. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain. 2000;16(2):67–72.
   Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Moore R, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;(4).
   Web of Science ®Google Scholar
• Zhou M, Chen N, He L, et al. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017(12):CD007963.
   Google Scholar
• Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42(2):229–236. DOI:https://doi.org/10.1016/S0028-3908(01)00172-1.
   PubMed Web of Science ®Google Scholar
• Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain. 2001;17(4):284–295.
   PubMed Web of Science ®Google Scholar
• Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16(6):705–714.
   Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104–2110.
   Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110(3):628–638.
   PubMed Web of Science ®Google Scholar
• Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14:167–184.
   PubMed Web of Science ®Google Scholar
• Boyle J, Eriksson MEV, Gribble L, et al. Randomized, Placebo-Controlled Comparison of Amitriptyline, Duloxetine, and Pregabalin in Patients With Chronic Diabetic Peripheral Neuropathic Pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012;35(12):2451–2458. DOI:https://doi.org/10.2337/dc12-0656.
   PubMed Web of Science ®Google Scholar
• Tölle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203–213.
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254–263.
   PubMed Web of Science ®Google Scholar
• Lee S. Pregabalin intoxication-induced encephalopathy with triphasic waves. Epilepsy Behav. 2012;25(2):170–173.
   PubMed Web of Science ®Google Scholar
• Duehmke RM, Derry S, Wiffen PJ, et al. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;(6).
   Google Scholar
• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151–162. DOI:https://doi.org/10.1185/03007995.2010.537589.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37(8):2302–2309. DOI:https://doi.org/10.2337/dc13-2291.
   PubMed Web of Science ®Google Scholar
• McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;(8).
   Google Scholar
• Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140:297–306.
   PubMed Web of Science ®Google Scholar
• The Capsaicin Study Group. The Capsaicin Study group. treatment of painful diabetic neuropathy with topical Capsaicin A multicenter, double-blind, vehicle-controlled study. Arch Intern Med. 1991;151(11):2225–2229. DOI:https://doi.org/10.1001/archinte.1991.00400110079017
   PubMedGoogle Scholar
• GmbH G. SmPC Qutenza 179mg cutaneous patch https://www.medicines.org.uk:. Electronic Medicines Compendium [cited 2020 Apr 24]; [ Available from: https://www.medicines.org.uk/emc/product/573/smpc.
   Google Scholar
• 16.2 Handling and prescribing information for the Qutenza 8% Capsaicin patch: food and drug administration [cited 2020 Apr 24]; [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf.
   Google Scholar
• Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42–53. DOI:https://doi.org/10.1016/j.jpain.2016.09.008.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(1):251. DOI:https://doi.org/10.1186/s12883-016-0752-7.
   PubMed Web of Science ®Google Scholar
• Polydefkis M, Hauer P, Sheth S, et al. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain. 2004;127(Pt 7):1606–1615.
   PubMedGoogle Scholar
• Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care. 2002;25:1699–1703.
   PubMed Web of Science ®Google Scholar
• Rayman G, Baker NR, Krishnan ST. Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Diabetes Care. 2003;26:2697–2698.
   PubMed Web of Science ®Google Scholar
• Basit A, Basit KA, Fawwad A, et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diabetes Res Care. 2016;4(1):e000148. DOI:https://doi.org/10.1136/bmjdrc-2015-000148.
   PubMed Web of Science ®Google Scholar
• Bell DS. Reversal of the symptoms of diabetic neuropathy through correction of Vitamin D deficiency in a Type 1 diabetic patient. Case Rep Endocrinol. 2012;2012:165056.
   PubMedGoogle Scholar
• Shehab D, Al-Jarallah K, Abdella N, et al. Prospective evaluation of the effect of short-term oral vitamin d supplementation on peripheral neuropathy in type 2 diabetes mellitus. Med Princ Pract. 2015;24(3):250–256.
   PubMed Web of Science ®Google Scholar
• Ghadiri-Anari A, Mozafari Z, Gholami S, et al. Dose vitamin D supplementations improve peripheral diabetic neuropathy? A before-after clinical trial. Diabetes Metab Syndr. 2019;13(1):890–893. DOI:https://doi.org/10.1016/j.dsx.2018.12.014.
   PubMed Web of Science ®Google Scholar
• Lee P, Vitamin CR. D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med. 2008;168(7):771–772.
   PubMedGoogle Scholar
• Valensi P, Le Devehat C, Richard JL, et al. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005;19(5):247–253. DOI:https://doi.org/10.1016/j.jdiacomp.2005.05.011.
   PubMed Web of Science ®Google Scholar
• Shillo P, Selvarajah D, Greig M, et al. Reduced Vitamin D levels in painful diabetic peripheral neuropathy. Diabet Med. 2019;36(1):44–51. DOI:https://doi.org/10.1111/dme.13798.
   PubMed Web of Science ®Google Scholar
• Soderstrom LH, Johnson SP, Diaz VA, et al. Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001-2004 NHANES. Diabet Med. 2012;29(1):50–55.
   PubMed Web of Science ®Google Scholar
• Alam U, Fawwad A, Shaheen F, et al. Improvement in neuropathy specific quality of life in patients with diabetes after Vitamin D supplementation. J Diabetes Res. 2017;2017:7928083.
   PubMed Web of Science ®Google Scholar
• Yammine K, Wehbe R, Assi C. A systematic review on the efficacy of vitamin D supplementation on diabetic peripheral neuropathy. Clin Nutr. 2020;S0261-5614(20):30045-30055. DOI:https://doi.org/10.1016/j.clnu.2020.01.022
   Google Scholar
• Lauria G, Ziegler D, Malik R, et al. The role of sodium channels in painful diabetic and idiopathic neuropathy. Curr Diab Rep. 2014;14(10):538.
   PubMed Web of Science ®Google Scholar
• Alsaloum M, Estacion M, Almomani R, et al. A gain-of-function sodium channel beta2-subunit mutation in painful diabetic neuropathy. Mol Pain. 2019;15:1744806919849802.
   Web of Science ®Google Scholar
• Kharatmal SB, Singh JN, Sharma SS. Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy. Mini Rev Med Chem. 2015;15(14):1134–1147.
   PubMed Web of Science ®Google Scholar
• Cholankeril R, Patel V, Perumpail BJ, et al. Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases. 2018;6:4.
   Google Scholar
• Dahan A, Brines M, Niesters M, et al. Targeting the innate repair receptor to treat neuropathy. Pain Rep. 2016;1(1):e566.
   PubMedGoogle Scholar
• Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20:658–666.
   PubMed Web of Science ®Google Scholar
• Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 2017;58(6):Bio52–bio60. DOI:https://doi.org/10.1167/iovs.16-21291.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616–2625. DOI:https://doi.org/10.1016/j.pain.2013.05.043.
   PubMed Web of Science ®Google Scholar
• Calandre EP, Morillas-Arques P, Molina-Barea R, et al. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord. 2011;12:95.
   PubMed Web of Science ®Google Scholar
• Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
   PubMed Web of Science ®Google Scholar
• Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469–476.
   PubMed Web of Science ®Google Scholar
• Alam U, Sloan G, Tesfaye S. Treating pain in diabetic neuropathy: current and developmental drugs. Drugs. 2020;80(4):363–384.
   PubMed Web of Science ®Google Scholar
• Smith MT, Wyse BD, Edwards SR. Small molecule angiotensin II type 2 receptor (AT(2)R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med. 2013;14(5):692–705.
   PubMed Web of Science ®Google Scholar
• Anand U, Facer P, Yiangou Y, et al. Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain. 2013;17(7):1012–1026. DOI:https://doi.org/10.1002/j.1532-2149.2012.00269.x.
   PubMed Web of Science ®Google Scholar
• Keppel Hesselink JM, Schatman ME. EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain. J Pain Res. 2017;10:439–443.
   PubMed Web of Science ®Google Scholar
• Rice ASC, Dworkin RH, McCarthy TD, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014;383(9929):1637–1647. DOI:https://doi.org/10.1016/S0140-6736(13)62337-5.
   PubMed Web of Science ®Google Scholar
• Tesfaye S. PL37: a new hope in the treatment of painful diabetic neuropathy?. Pain Manag. 2016;6(2):129–132.
   PubMed Web of Science ®Google Scholar
• Thibault K, Elisabeth B, Sophie D, et al. Antinociceptive and anti-allodynic effects of oral PL37, a complete inhibitor of enkephalin-catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine. Eur J Pharmacol. 2008;600(1–3):71–77.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kayser V, Guilbaud G. Antinociceptive effect of systemic kelatorphan, in mononeuropathic rats, involves different opioid receptor types. Eur J Pharmacol. 1994;264(1):61–67.
   PubMed Web of Science ®Google Scholar
• Coudoré-Civiale MA, Méen M, Fournié-Zaluski MC, et al. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats. Br J Pharmacol. 2001;133(1):179–185.
   PubMed Web of Science ®Google Scholar
• Garcia-Guzman M, Stuhmer W, Soto F. Molecular characterization and pharmacological properties of the human P2X3 purinoceptor. Brain Res Mol Brain Res. 1997;47(1–2):59–66.
   PubMedGoogle Scholar
• Fabbretti E, P2X3 ATP. receptors and neuronal sensitization. Front Cell Neurosci. 2013;7:236.
   PubMed Web of Science ®Google Scholar
• Garceau D, Chauret N. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulm Pharmacol Ther. 2019;56:56–62.
   PubMed Web of Science ®Google Scholar
• Marucci G, Dal Ben D, Buccioni M, et al. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Expert Opin Ther Pat. 2019;29(12):943–963. DOI:https://doi.org/10.1080/13543776.2019.1693542.
   PubMed Web of Science ®Google Scholar
• Shin EJ, Nah SY, Chae JS, et al. Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats. Neurochem Int. 2007;50(6):791–799. DOI:https://doi.org/10.1016/j.neuint.2007.01.008.
   PubMed Web of Science ®Google Scholar
• Shin EJ, Nah SY, Kim WK, et al. The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan. Br J Pharmacol. 2005;144(7):908–918. DOI:https://doi.org/10.1038/sj.bjp.0705998.
   PubMed Web of Science ®Google Scholar
• Weissman AD, Su TP, Hedreen JC, et al. Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther. 1988;247(1):29–33.
   PubMed Web of Science ®Google Scholar
• Roden DM. Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs. Card Electrophysiol Clin. 2014;6(4):695–704.
   PubMedGoogle Scholar
• Thisted RA, Klaff L, Schwartz SL, et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. Clin Ther. 2006;28(10):1607–1618. DOI:https://doi.org/10.1016/j.clinthera.2006.10.005.
   PubMed Web of Science ®Google Scholar
• Shaibani AI, Pope LE, Thisted R, et al. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med. 2012;13(2):243–254.
   PubMed Web of Science ®Google Scholar
• Freeman R. Diabetic autonomic neuropathy. Handb Clin Neurol. 2014;126:63–79.
   PubMedGoogle Scholar
• Martin CL, Albers JW, Pop-Busui R, Group DER. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):31–38. DOI:https://doi.org/10.2337/dc13-2114.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553–1579.
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–962. DOI:https://doi.org/10.2337/diacare.28.4.956.
   PubMed Web of Science ®Google Scholar
• Valensi P, Paries J, Attali JR. French Group for R, Study of Diabetic N. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications–the French multicenter study. Metab. 2003;52(7):815–820.
   PubMed Web of Science ®Google Scholar
• Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care. 2004;27(12):2942–2947. DOI:https://doi.org/10.2337/diacare.27.12.2942.
   PubMed Web of Science ®Google Scholar
• Witte DR, Tesfaye S, Chaturvedi N, et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005;48(1):164–171. DOI:https://doi.org/10.1007/s00125-004-1617-y.
   PubMed Web of Science ®Google Scholar
• Charles M, Fleischer J, Witte DR, et al. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. Diabetologia. 2013;56(1):101–108. DOI:https://doi.org/10.1007/s00125-012-2744-5.
   PubMed Web of Science ®Google Scholar
• Charles M, Ejskjaer N, Witte DR, et al. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care. 2011;34(10):2244–2249.
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Stevens MJ, Raffel DM, et al. Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia. 2013;56(8):1835–1844. DOI:https://doi.org/10.1007/s00125-013-2942-9.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Casellini C, Parson HK, et al. Cardiac autonomic neuropathy in diabetes: a predictor of cardiometabolic events. Front Neurosci. 2018;12:591.
   PubMed Web of Science ®Google Scholar
• Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615–624.
   PubMed Web of Science ®Google Scholar
• Kaufmann H. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn? Clin Auton Res. 2017;27(Suppl 1):1–3.
   Google Scholar
• Parkman HP, Hasler WL, Fisher RS, et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127(5):1592–1622.
   PubMed Web of Science ®Google Scholar
• Alam U, Asghar O, Malik RA. Diabetic gastroparesis: therapeutic options. Diabetes Ther. 2010;1(1):32–43.
   PubMedGoogle Scholar
• Kumar M, Chapman A, Javed S, et al. Treatment of diabetic gastroparesis. Clin Ther. 2018;40(6):850–861.
   PubMed Web of Science ®Google Scholar
• Murao S, Serotonin HH. 5-HT3 receptor antagonist for treatment of severe diabetic diarrhea. Diabetes Care. 2010;33(3):e38.
   PubMedGoogle Scholar
• Ogbonnaya KI, Arem R. Diabetic diarrhea. Pathophysiology, diagnosis, and management. Arch Intern Med. 1990;150(2):262–267.
   PubMedGoogle Scholar
• Lue TF, Brant WO, Shindel A, et al. Sexual Dysfunction in Diabetes[Updated 2017 Feb 27]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000:1-5. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279101/
   Google Scholar
• Várkonyi T, Chapter KP. 16 - Sexual dysfunction in diabetes. In: Zochodne DW, Malik RA, editors. Handbook of Clinical Neurology. Vol. 126. San Diego: Elsevier Science & Technology Books; 2014. p. 223–232.
   Google Scholar
• Kouidrat Y, Pizzol D, Cosco T, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabetic Med. 2017;34(9):1185–1192. DOI:https://doi.org/10.1111/dme.13403.
   PubMed Web of Science ®Google Scholar
• Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. Postgrad Med J. 2017;93(1105):679–685.
   PubMed Web of Science ®Google Scholar
• Wang H, Yuan J, Hu X, et al. The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Curr Med Res Opin. 2014;30(8):1565–1571.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med. 1998;338(20):1397–1404.
   PubMed Web of Science ®Google Scholar
• Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50(2):351–359. DOI:https://doi.org/10.1016/j.eururo.2006.02.052.
   PubMed Web of Science ®Google Scholar
• Montorsi F, Aversa A, Moncada I, et al. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naive to PDE5 inhibitors. J Sex Med. 2011;8(9):2617–2624. DOI:https://doi.org/10.1111/j.1743-6109.2011.02353.x.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002;23(6):763–771.
   PubMed Web of Science ®Google Scholar
• Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151(9):650–661. DOI:https://doi.org/10.7326/0003-4819-151-9-200911030-00150.
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902–912. DOI:https://doi.org/10.1016/j.eururo.2013.01.012.
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828–849. DOI:https://doi.org/10.1016/j.clinthera.2018.04.001.
   PubMed Web of Science ®Google Scholar
• Azmi SM, Nelson M, Alam A, et al. Are we using the right tests to diagnose diabetic neuropathy? Med Matters Diabetes. 2018.
   Google Scholar
• Gæde P, Lund-Andersen H, Parving H-H PO. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N Engl J Med. 2008;358(6):580–591.
   PubMed Web of Science ®Google Scholar
• Javed S, Alam U, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res. 2018;11:1559–1566.
   PubMed Web of Science ®Google Scholar
• Burgess J, Javed S, Frank B, et al. Mirogabalin besylate in the treatment of neuropathic pain. Drugs Today (Barc). 2020;56(2):135–149.
   PubMed Web of Science ®Google Scholar
• Gabapentin 600 mg film-coated tablets electronic medicines compendium 2019 [cited 2020 Apr 24]. Available from: https://www.medicines.org.uk/emc/product/4721.
   Google Scholar
• Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;(6).
   Web of Science ®Google Scholar
• Pregabalin Accord Healthcare 300 mg hard capsules Electronic Medicines Compendium 2018 [cited 2020 Apr 24]. Available from: https://www.medicines.org.uk/emc/product/805.
   Google Scholar
• Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2019. DOI:https://doi.org/10.1002/14651858.CD007076.pub3
   Google Scholar
• Lamotrigine 100 mg tablets electronic medicines compendium. 2018 [cited 2020 Apr 24]. Available from: https://www.medicines.org.uk/emc/product/4739/smpc.
   Google Scholar
• Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;(12).
   Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;(4).
   Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev. 2011;(1).
   Google Scholar
• Carbagen 400 mg tablets: electronic medicines compendium. 2009 [cited 2020 Apr 20]. Available from: https://www.medicines.org.uk/emc/product/4377/smpc.
   Google Scholar
• Morphgesic SR60mg Tablets: electronic medicines compendium. 2019 [cited 2020 Jul 20]. Available from: https://www.medicines.org.uk/emc/product/4697/smpc.
   Google Scholar
• Cooper TE, Chen J, Wiffen PJ, et al. Morphine for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;(5).
   Web of Science ®Google Scholar
• Tramadol 50 mg capsules Electronic Medicines Compendium electronic medicines compendium 2018 [cited 2020 Apr 20]. [Available from: https://www.medicines.org.uk/emc/product/7123/smpc.
   Google Scholar
• Freo U, Romualdi P, Kress HG. Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res. 2019;Volume 12:1537.
   Web of Science ®Google Scholar
• Palexia SR prolonged release tablets electronic medicines compendium. [cited 2020 Apr 20]. Available from: https://www.medicines.org.uk/emc/product/5158/smpc.
   Google Scholar
• Nortriptyline 50mg film-coated tablets EMC:. EMC; 2019 [ updated 08/March/2019. Available from: https://www.medicines.org.uk/emc/product/9970/smpc.
   Google Scholar
• Derry S, Wiffen PJ, Aldington D, et al. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(1).
   Google Scholar
• Hearn L, Moore RA, Derry S, et al. Desipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;(9).
   Google Scholar
• NORPRAMIN (desipramine hydrochloride) tablets USP:. RxList; [ updated November/27/2018 [cited 2020 Apr 20]. Available from: https://www.rxlist.com/norpramin-drug.htm#medguide.
   Google Scholar
• Duloxetine 60mg gastro-resistant capsules, hard EMC: EMC; [ updated 17/January/2020 [cited 2020 Apr 20]. Available from: https://www.medicines.org.uk/emc/product/10518/smpc.
   Google Scholar
• Fluoxetine 60mg capsules EMC: EMC; [cited 2020 Apr 20]. Available from: https://www.medicines.org.uk/emc/product/4995/smpc.
   Google Scholar
• Derry S, Wiffen PJ, Moore RA, et al. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014(7).
   Web of Science ®Google Scholar
• Versatis 700mg medicated plaster EMC: EMC; 2017 [cited 2020 Apr 20]. [Available from: https://www.medicines.org.uk/emc/product/290/smpc#ORIGINAL.Accessed: 20/4/20].
   Google Scholar
• Derry S, Rice ASC, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;(1).
   Web of Science ®Google Scholar
• Qutenza 179mg cutaneous patch EMC: EMC; 2014. [ updated 15 May 2014. Available from: https://www.medicines.org.uk/emc/product/573/smpc.
   Google Scholar
• NICE. Neuropathic pain in adults: pharmacological management in non-specialist settings 2013 [July 2019: [Available from: https://www.nice.org.uk/guidance/cg173.
   Google Scholar
• Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(7).
   Google Scholar
• Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2012;(9).
   Web of Science ®Google Scholar
• Wanigasekera V, Mezue M, Andersson J, et al. Disambiguating pharmacodynamic efficacy from behavior with neuroimaging: implications for analgesic drug development. Anesthesiology. 2016;124(1):159–168.
   PubMed Web of Science ®Google Scholar